Matthias Götte, PhD
Matthias Götte obtained his PhD degree in 1997 at the Max-Planck-Institute for Biochemistry in Martinsried, Germany. In 2000, following his postdoctoral training at the Lady Davis Institute for Medical Research in Montreal, he joined the faculty at McGill University in the Department of Microbiology & Immunology. In 2014, he accepted the position as Chair of the Medical Microbiology & Immunology Department at the University of Alberta (U of A) in Edmonton, Alberta. In 2023, he completed a second term as Chair and is now the Director of U of A’s research & training program in pandemic preparedness; Striving for Pandemic Preparedness - The Alberta Research Consortium. Research in Götte’s lab is focused on structure, function and inhibition of viral polymerases. Emphasis is placed on drug discovery, development and resistance related to viruses with high epidemic potential. Early in the pandemic, his team elucidated the mechanism of action of remdesivir that became later the first approved antiviral drug for the treatment of COVID-19.
Publications
- RE: Avian Influenza and use of the H5N1 Vaccine to Prevent Zoonotic Infection in Canada
- Mechanism and Spectrum of Inhibition of a 4′-cyano Modified Nucleotide Analog against Diverse RNA Polymerases of Prototypic Respiratory RNA Viruses
- A Post-Assembly Conformational Change makes the SARS-CoV-2 Polymerase Elongation Competent
- Mechanism and Spectrum of Inhibition of Viral Polymerases by 2′-deoxy-2′-β-fluoro-4′-azidocytidine or Azvudine
- Single-Molecule Assay Reveals Binding Dynamics of SARS-CoV-2 Polymerase Components and Provides a New Tool to Distinguish Polymerase Inhibitors
- Bunyaviral Cap-Snatching Endonuclease Activity and Inhibition with Baloxavir-like Inhibitors in the Context of Full-Length L Proteins
- Mechanism of Inhibition of the Active Triphosphate Form of 2′-α-Fluoro,2′-β-bromouridine against Yellow Fever Virus RNA-Dependent RNA Polymerase